Angiodynamics, Inc. ((ANGO)) has held its Q1 earnings call. Read on for the main highlights of the call.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The recent earnings call for AngioDynamics, Inc. painted a picture of robust growth and optimism, particularly in the Med Tech and Mechanical Thrombectomy sectors. While the company celebrated increased guidance and strong performance across various segments, challenges such as tariff expenses and an ongoing adjusted net loss were also acknowledged.
Significant Revenue Growth
AngioDynamics reported a notable 12.2% increase in overall revenue, reaching $75.7 million. This growth was driven by a remarkable 26.1% rise in the Med Tech segment and a modest 2.3% increase in the Medical Device segment.
Med Tech Segment Success
The Med Tech segment now accounts for 47% of AngioDynamics’ total revenue, up from 41% a year ago. This segment has experienced a compound annual growth rate of 25% over the past five years, underscoring its critical role in the company’s portfolio.
Auryon Platform Performance
The Auryon platform continued its impressive trajectory, delivering $16.5 million in revenue with a 20.1% growth compared to the previous year. This marks the 17th consecutive quarter of double-digit year-over-year growth for Auryon.
Mechanical Thrombectomy Growth
Mechanical Thrombectomy revenue surged by 41.2% year-over-year, fueled by significant contributions from AngioVac and AlphaVac products.
NanoKnife Expansion
NanoKnife revenue saw a 26.7% increase, driven by expanded prostate indications and the anticipated effectiveness of CPT I codes starting in January.
Increased Guidance for Fiscal 2026
AngioDynamics raised its net sales guidance for fiscal 2026 to a range of $308 million to $313 million. The company expects Med Tech net sales to grow between 14% and 16%, reflecting a strategic focus on this high-growth area.
Tariff Impact on Gross Margin
Despite improvements in gross margin, which reached 55.3%, the company faced $1.7 million in tariff expenses. These are expected to impact the full fiscal year by $4 million to $6 million.
Adjusted Net Loss
The company reported an adjusted net loss of $4.2 million, or $0.10 per share, which is a slight improvement from last year’s $4.4 million loss.
Forward-Looking Guidance
AngioDynamics provided a positive outlook for the future, with an increased revenue guidance for fiscal 2026 and a focus on strategic investments in R&D and commercial teams. The company anticipates continued growth in its Med Tech segment and sustained profitability through its strategic initiatives.
In conclusion, AngioDynamics, Inc.’s earnings call highlighted a strong growth trajectory with significant contributions from the Med Tech and Mechanical Thrombectomy segments. While challenges such as tariff expenses and adjusted net losses persist, the company’s increased guidance and strategic investments indicate a promising future.